The online version of this article (doi:10.1186/s12885-017-3193-9) contains supplementary material, which is available to authorized users.
Glioblastoma multiforme (GBM) is the most common, invasive and deadly primary type of malignant brain tumor. The Phosphatidylinositol-3-Kinase/AKT (PI3K/AKT) pathway is highly active in GBM and has been associated with increased survival and resistance to therapy. The aim of this study is to investigate the effects of AKT inhibition in combination with the current standard of care which consists of irradiation and temozolomide (TMZ) on human malignant glioma cells growing adherent and as multicellular spheroids in vitro.
The effects of the allosteric inhibitor MK2206 combined with irradiation and TMZ were assessed on glioma cells growing adherent and as multicellular 3D spheroids. The interaction was studied on proliferation, clonogenic cell survival, cell invasion, −migration and on expression of key proteins in the PI3K-AKT pathway by western blot.
A differential effect was found at low- (1 μM) and high dose (10 μM) MK2206. At 1 μM, the inhibitor reduced phosphorylation of Thr308 and Ser473 residues of AKT in both adherent cells and spheroids. Low dose MK2206 delayed spheroid growth and sensitized spheroids to both irradiation and TMZ in a synergistic way (Combination index <0.35). In contrast, neither low nor high dose MK2206 did enhance therapy sensitivity in adherent growing cells. Effective inhibition of invasion and migration was observed only at higher doses of MK2206 (>5 μM).
The data show that a 3D spheroid model show different sensitivity to irradiation when combined with AKT inhibition. Thereby we show that MK2206 has potential synergistic efficacy to the current standard of care for glioma patients.
Additional file 1: Figure S1. A) Number of cells invaded through matrigel after 16 h in the presence of 4 Gy combined with 1 μM (Left) or 10 μM (Right) MK2206. Error bars represent SD over 3 replicates, * = p < 0.05. B) U87 cells untreated. Migration of U87 cells into wound up to 8 h (Left). Migration of U87 cells out of attached spheroids up to 4 days after spheroid plating (Right). (PDF 356 kb)12885_2017_3193_MOESM1_ESM.pdf
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. Springer. Berlin Heidelberg. 2016;131:1–18.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol Elsevier Ltd. 2009;10:459–66. CrossRef
Campos B, Olsen LR, Urup T, Poulsen HS. A comprehensive profile of recurrent glioblastoma. Oncogene Nature Publishing Group. 2016;1–7
Joy A, Kapoor M, Georges J, Butler L, Chang Y, Li C, et al. The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. J Neuro-Oncol. Springer US. 2016;130(1):43-52.
Toulany M, Lee K-J, Fattah KR, Lin Y-F, Fehrenbacher B, Schaller M, et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res. 2012;10(7):945-57.
Narayan RS, Fedrigo CA. Stalpers LJ a, Baumert BG, Sminia P. Targeting the Akt-pathway to improve radiosensitivity in glioblastoma. Curr. Pharm. Des. 2013;19:951–7.
Toulany M, Rodemann HP. Potential of Akt mediated DNA repair in radioresistance of solid tumors overexpressing erbB-PI3K-Akt pathway. Transl Cancer Res. 2013;2(3):190–202.
Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. Nat Publ Group. 2013;10:143–53.
Tao K, Yin Y, Shen Q, Chen Y, Li R, Chang W, et al. Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. Biomed reports. 2016;4:365–8.
Lin Y-H, Chen BY-H, Lai W-T, Wu S-F, Guh J-H, Cheng A-L, et al. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedeberg's Arch Pharmacol. 2015;388:19–31. CrossRef
Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 1977;252:6438–42. PubMed
Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 2016;1–14
Eke I, Cordes N. Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. Radiother Oncol Elsevier Ireland Ltd. 2011;99:271–8. CrossRef
Mehta M. Khan a., Danish S, Haffty BG, Sabaawy HE. Radiosensitization of primary human glioblastoma stem-like cells with low-dose AKT inhibition. Mol Cancer Ther. 2015;1171–81
- The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures
Ravi S. Narayan
Carlos A. Fedrigo
Lukas J.A. Stalpers
Brigitta G. Baumert
Ben J. Slotman
Bart A. Westerman
Godefridus J. Peters
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II